Literature DB >> 4121004

Marked immunosuppression with minimal myelosuppression by bleomycin in vitro.

G Tisman, V Herbert, L T Go, L Brenner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4121004

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  Target-induced activation of DNAzyme for highly sensitive colorimetric detection of bleomycin via DNA scission.

Authors:  Xiaofei Liao; Mengyan Li; Li Zou
Journal:  RSC Adv       Date:  2022-06-22       Impact factor: 4.036

2.  Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor.

Authors:  Hiroaki Iwamoto; Kouji Izumi; Ariunbold Natsagdorj; Tomoyuki Makino; Takahiro Nohara; Kazuyoshi Shigehara; Yoshifumi Kadono; Atsushi Mizokami
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

3.  Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors.

Authors:  Ryunosuke Nakagawa; Hiroaki Iwamoto; Tomoyuki Makino; Suguru Kadomoto; Hiroshi Yaegashi; Masashi Iijima; Shohei Kawaguchi; Takahiro Nohara; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Atsushi Mizokami
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

4.  Effective Penetration of a Liposomal Formulation of Bleomycin through Ex-Vivo Skin Explants from Two Different Species.

Authors:  Giulia Ferrari; Lisa Y Pang; Fabio De Moliner; Marc Vendrell; Richard J M Reardon; Andrew J Higgins; Sunil Chopra; David J Argyle
Journal:  Cancers (Basel)       Date:  2022-02-21       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.